Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances.
A subset of gastrointestinal neuroendocrine tumours (carcinoids and pancreatic endocrine tumours) show aggressive growth. Early identification of this subset is essential for management; however, clinical, laboratory and histologic features frequently fail to achieve this. Currently, there is an increased understanding of the molecular pathogenesis/changes in neuroendocrine tumours and this may identify important prognostic factors and possibly, new treatments. Recent findings and progress in this area are briefly reviewed in this article.
Corleto
V D
VD
Division of Digestive and Liver Diseases, University La Sapienza, Rome, Italy.
Delle Fave
G
G
Jensen
R T
RT
D015408:Gastrinoma / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D005770:Gastrointestinal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000401:mortality; D016147:Genes, Tumor Suppressor; D006801:Humans; D007150:Immunohistochemistry; D009154:Mutation; D018358:Neuroendocrine Tumors / Q000235:genetics* / Q000378:metabolism / Q000401:mortality; D009857:Oncogenes; D010982:Platelet-Derived Growth Factor / Q000378:metabolism*; D015996:Survival Rate; D016211:Transforming Growth Factor alpha / Q000378:metabolism*
D010982:Platelet-Derived Growth Factor; D016211:Transforming Growth Factor alpha